Agoracom Blog Home

Archive for the ‘All Recent Posts’ Category

Expand uses for medical marijuana $MCOA.us $TBP.ca

Posted by AGORACOM-JC at 10:17 AM on Monday, February 27th, 2017
  • New Jerseyans with chronic pain can receive the kind of relief from medicinal marijuana they cannot get from any other drug
  • In many cases pot does a better job reducing the pain, and without unwanted side effects.
  • Limiting its benefits because of outdated notions about the dangers of marijuana use is misguided
On Wednesday advocates for expanding eligible conditions under New Jersey’s medical marijuana program will have their first formal chance to make their case before a special panel created to consider such pleas.

Loosening some of the reins on medical marijuana is long overdue, and we urge panel members to enter the process with an open mind and a willingness to broaden the potential to bring relief to those in pain.

If they do, it will mark a significant contrast to most anything we’ve seen from Gov. Chris Christie’s administration, which has been reluctant to implement the program from the start and has thrown up repeated obstacles that have effectively limited distribution.

Christie inherited the program from former Gov. Jon Corzine, who legalized medical marijuana but left office before any of the particulars of the new law had been put in place. That left Christie — an opponent of legalization — to oversee the details, providing ample opportunity for delay while establishing new regulations.

There was little point to the foot-dragging other than to burnish Christie’s conservative credentials in opposing any form of pot legalization. The governor continues to cling to the widely discredited argument of marijuana as a gateway drug leading to more addictive and more lethal substances. The end result was to deny relief to patients experiencing chronic pain from certain medical conditions, relief that should have been available to them under the law, except for the implementation delays.

Even now, however, patient advocates say New Jersey’s medical marijuana program is needlessly restrictive, failing to include many health issues that should be covered by the law. That’s what Wednesday’s meeting of the Medicinal Marijuana Review Panel could help correct. The hearing is an outgrowth of a 2014 lawsuit that challenged the unacceptably long implementation process.

In July the state health department sought written requests for illnesses to be added to the eligibility list, and among those offered were conditions generating chronic pain such as osteoarthritis and Lyme disease. In September Christie surprised many by making medical marijuana available to post-traumatic stress disorder sufferers, the first new condition added under the law.

The review panel should follow that lead, even if Christie would rather it not. We’ve come a long way in our understanding of the pros and cons of marijuana use for medicinal purpose. Public support to broaden legalization continues to grow across the nation. We continue to oppose it in New Jersey, although attempts to legalize it here are sure to intensify once Christie leaves office.

In the meantime, however, many New Jerseyans with chronic pain can receive the kind of relief from medicinal marijuana they cannot get from any other drug. In many cases pot does a better job reducing the pain, and without unwanted side effects. Limiting its benefits because of outdated notions about the dangers of marijuana use is misguided.

The hearing will begin at 10 a.m. Wednesday in Trenton, at the War Memorial, Turning Point Conference Room at 1 Memorial Drive.

Source: http://www.app.com/story/opinion/editorials/2017/02/21/medical-marijuana-new-jersey-health-conditions/98212062/

AGORACOM Welcomes Back Grizzly Discoveries (GZD: TSX-V) with World Class Gold and Base Metal Deposits in British Columbia; and Diamonds in Alberta $GZD.ca

Posted by AGORACOM-JC at 12:30 PM on Thursday, February 23rd, 2017

Gzdnew

WHY GRIZZLY DISCOVERIES?

  • More than 9 million oz Au produced or as resources in a radius of less than 70KM to Greenwood project
  • World class gold and base metal deposits in British Columbia; and diamonds in Alberta
  • Holds, or has an interest in, metallic and industrial mineral permits for potash totaling more than 364,000 acres along the Alberta-Saskatchewan border
  • Four precious-base metal properties in British Columbia totaling over 235,000 acres. Grizzly also currently holds more than 231,000 acres in diamond properties, which host diamondiferous kimberlites in the Buffalo Head Hills and Birch Mountains of Alberta

EXPLORATION HIGHLIGHTS

  • Drillholes with up to 31.1% K2O results from assays on recent Grizzly drill program
  • Historic Unity Potash Mine 45 km east of existing GZD lands
  • Agrium Vanscory Potash Mine 200 km east of GZD lands
  • Significant Potash in drill core or indicated by gamma logs at depths ranging from 1,060m to 1,675m
  • Temperatures at those depths range from about 50oC to 75oC. Optimal temperature for solution mining is approximately 75oC.

POTASH DEMAND AND GROWTH

  • According to industry estimates, Canada has Potash resources of 7.3 billion tonnes – roughly 52% of the world’s supply.
  • Currently 11 mines in Saskatchewan produce the majority of Canada’s 35% contribution to the world’s annual production.
  • The arable land per person in the world is declining, and weather patterns are becoming more volatile and extreme, fuelling demand for Potash which increases the yield per acre approximately 40%.

BC PRECIOUS METALS

Greenwood Gold District

Portions of Grizzly’s Greenwood Project being explored by Kinross is 100% owned by Grizzly Discoveries Inc. and includes 131 claims that form a contiguous package totaling approximately 27,346 hectares, representing approximately one third of Grizzly’s land holdings at Greenwood. Under the terms of a September 2015 agreement, KG Exploration (Canada) Inc. can earn a 75% interest on the optioned land pursuant to an Option Agreement with Grizzly on portions of its land holdings in southeastern British Columbia by incurring US$3 million in exploration expenditures over a 5 year period. By the second anniversary of the agreement, 750 metres of diamond drilling must be completed along with US$750,000 in expenditures by September 23, 2017.

 ALBERTA DIAMONDS

  • Following 12 drill holes, 3 new diamond bearing kimberlites were discovered in 2008 at the Buffalo Head Hills property.
  • Grizzly has more than 200,000 acres surrounding Diamondex & Shore Gold in the Buffalo Head Hills.
  • Two kimberlite pipes look very promising and need bulk sampling which is being planned for future dates due to Grizzly’s current potash focus.
  • Land rights are valid for 2 to 5 years based on existing development work done on properties by Grizzly.

Buffalo Head Hills Diamond Property, Alberta
A Renewed Interest in diamonds

Renewed interest in diamond exploration during 2015 and 2016 has prompted re-evaluation of Grizzly’s Buffalo Head Hills Diamond Project in north-central Alberta, which is located approximately 330 kilometres northwest of Edmonton and is easily accessed during summer and winter by a large network of roads and cutlines. Based upon an internal review of all data, the Company has staked additional permits of highly prospective lands for diamond-bearing kimberlites in the Buffalo Head Hills area. Grizzly’s total land position includes 11 permits that encompass approximately 220,000 acres.

12 MONTH STOCK CHART

Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 8:45 AM on Thursday, February 23rd, 2017

Tbp large

  • Announces launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers
  • Phase I clinical research is a classical pharmaceutical study in the development of a new drug. The trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination

OTTAWA, ONTARIO–(Feb. 23, 2017) - PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce the launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers.

The Phase I clinical research is a classical pharmaceutical study in the development of a new drug. The trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination. Algorithme Pharma has already begun recruiting subjects for the Phase I trial. This study is a pivotal safety trial as it will allow Tetra to understand the adverse effects of smoking Cannabis and associate the outcomes, such as cognitive function, to plasma levels of THC and CBD. The study will provide Tetra with the data necessary to discuss with Health Canada and FDA the potential risks in patient populations and discuss marketing requirements for specific indications.

The pharmacokinetic profile and safety data generated by the Phase I trial will allow Tetra to finalize the design of its Phase II-III clinical trial that will assess the safety and efficacy of PPP001 in cancer patients with uncontrolled pain. PPP001 is being developed for cancer patients with moderate-to-severe pain and that are not adequately controlled with the standard of care. Approximately 50% of cancer patients suffer from pain and more than 600,000 of these patients suffer from moderate-to-severe pain. In the USA, there are over 4 million cancer patients and this pain market is valued at over $5 billion USD.

We are very pleased to announce that the start of the Phase I clinical trial activities as this keeps the company on track in its development of PPP001″, commented Mr, Andre Rancourt. “With PPP001 and the mucoadhesive AdVersa® controlled-release tablet, Tetra is positioning itself to become a major player in the cancer pain therapy market, added Mr. Rancourt.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

 

Tartisan Announces Signing of a LOI for the Purchase of the Don Pancho Zinc-Lead-Silver Property in Peru $TTC.ca

Posted by AGORACOM-JC at 8:03 AM on Wednesday, February 22nd, 2017

Tartisan logo copy

  • letter of intent with Duran Ventures Inc. (V-DRV) for the purchase of the Don Pancho zinc-lead-silver property in Peru
  • Agreement with Duran to acquire 100% of the Don Pancho polymetallic zinc-lead-silver project located in the Department of Lima Peru, 110 kilometers north-northeast of Lima, comprising one concession of 600 hectares

Toronto, Ontario (FSCwire)Tartisan Resources Corp. (CSE: TTC) (“Tartisan”, or the “Company”) is pleased to announce the signing of a letter of intent with Duran Ventures Inc. (V-DRV) ( “Duran”) for the purchase of the Don Pancho zinc-lead-silver property in Peru.

Letter of Intent

Tartisan Resources Corp. has entered into an agreement with Duran to acquire 100% of the Don Pancho polymetallic zinc-lead-silver project located in the Department of Lima Peru, 110 kilometers north-northeast of Lima, comprising one concession of 600 hectares and is the subject of a NI 43-101 compliant Report prepared in December 2014 available for viewing on SEDAR.

The project is located in a prolific polymetallic mineral belt in central Peru with several operating mines in the area including the world class Iscaycruz and Yauliyacu polymetallic mines operated by Glencore-Xtrata Plc located 50 kilometers to the north-northwest. Trevali Mining Corporation’s Santander silver-lead- zinc mine is located 9 kilometers to the east and Buenaventura’s silver-lead-zinc Uchucchacua mine is located 63 kilometers to the north, (10 million ounces of silver produced in 2011). Infrastructure is considered excellent with ready access and a power line crossing the property en route to the Santander mine.

Don Pancho Project

Previous exploration on the property included an extensive surface mapping and sampling program, geophysics and a 2000 metre diamond drilling program of 6 holes conducted by a private Peruvian company.

Mapping and sampling shows an extensive NNW-SSE trending breccia zone measuring over 800 metres in length and 150 to 200 metres in width. There are numerous old workings and underground drifts located within this zone. The 2014 diamond drilling program shows large intersections of polymetallic mineralization, including 40 metres of 0.88% Zn, 0.40% Pb and 7.7 g/t Ag, 22.65 metres of 1.00% Zn, 0.26% Pb and 6.85 g/t Ag and 1.15 metres of 4.38% Zn, 3.25% Pb and 61.1 g/t Ag, (see Duran’s Press Release September 2, 2014). Surface sampling from the previous operator has revealed very interesting values, including 13.9 metres of 28.1 g/t Ag, 2.43% Pb, and 2.42% Zn, 2.8 metres of 28.1g/t Ag, 1.06% Pb, and 9.07% Zn and 13 metres of 8.38g/t Ag, 0.39% Pb, and 2.22% Zn. Sampling of underground workings in Yanapallaca area before the previous operators retuned 106 g/t Ag, 3.26% Pb and 17.56% Zn over 2.00 metres. (see 43-101 Technical Report on Don Pancho filed December 30th, 2014 on Sedar). Please note that the true width of the mineralization both on the surface and underground workings cannot yet be determined as the controls of the mineralization is yet to be fully understood.

A program of geophysics, diamond drilling and underground drifting is envisioned. Structural analysis on the geology suggests previous drilling did not properly test the potential of the property.

The Agreement will permit Tartisan to acquire a 100% undivided interest in the property by paying $50,000 and issuing 500,000 common shares by March 31, 2017. Upon completion of 5,000 metres of drilling and/or underground development a further 150,000 shares are payable and if a NI 43-101 compliant resource is published, a further 150,000 shares are payable and if the Company loses control of the project either by sale or joint-venture, a further 200,000 shares are payable. Duran will retain a 2% net smelter return royalty, of which half (1%) can be purchased by Tartisan for US$500,000.

Tartisan Resources Corp. common shares are listed on the Canadian Securities Exchange (CSE:TTC). Currently, there are 63,287,629 shares outstanding (82,759,982 fully diluted).

For further information on Tartisan, please contact Mr. D. Mark Appleby, President & CEO and a Director of the Company, at 416-804-0280 (mark@tartisanresources.com). Additional information about Tartisan can be found at the Company’s website at www.tartisanresources.com or on SEDAR at www.sedar.com. For further information on Duran, please contact Jeff Reeder at 647-302-3290 (info@duranventuresinc.com) or www.duranventuresinc.com

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

Jeff Reeder P.Geo. a qualified person in the context of NI 43-101 has reviewed and approved the technical content of this News Release
To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/Tartisan02222017.pdf

Source: Tartisan Resources Corp. (CSE:TTC)

Tetra Bio-Pharma Announces Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 12:39 PM on Thursday, February 16th, 2017

Tbp large

  • Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis
  • We are very pleased to announce the authorization of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

OTTAWA, ONTARIO–(Feb. 16, 2017) - PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers. The CTA was submitted to Health Canada and the research ethics review board in December 2016. On January 3, 2017, the clinical trial received approval from the Institutional Review Board. TPD issued a Letter of Authorization for the conduct of the Phase I clinical trial on February 16, 2017. Algorithme Pharma will be initiating the clinical trial activities in the coming weeks.

²We are very pleased to announce the authorisation of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

“This trial is part of Tetra’s commitment to develop medical Cannabis as a prescription drug for patients. The outcome of this trial is going to have significant implications in medical Cannabis research as it is a first pharmaceutical clinical trial assessing the effects of smoked Cannabis on cognitive function in healthy volunteers” said Mr. Rancourt, Chief Executive Officer

Earlier this month, Tetra and IntelGenx announced the co-development of Dronabinol AdVersa® Mucoadhesive controlled-release tablet for the management of Breakthrough Cancer Pain. The significant advantage of the Mucoadhesive technology was demonstrated in a Phase I clinical trial. The study demonstrated the delayed-release of THC avoids a rapid increase in the blood. ²With both of these products in clinical development, Tetra is on track with its objective to bring Cannabis-based prescription drugs to the market. Both of these products are promising alternatives in the battle for the reduction of opioids and improving quality of life in patients with chronic pain², added Dr. Chamberland.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Discusses Clinical Program in New Interview with CFN Media

Posted by AGORACOM-JC at 9:19 AM on Tuesday, February 14th, 2017

Tbp large

  • Exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CNSX: TBP) in its clinical trial program
  • Interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer

SEATTLE, WA–(Feb 14, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CNSX: TBP) in its clinical trial program. The interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer.

Medical marijuana may be legal for roughly 60% of the U.S. population, but the cost of the drug remains prohibitive for many patients in need. Tetra Bio-Pharma aims to undergo FDA-sanctioned clinical trials for dried medical marijuana to secure prescription drug coverage from insurance companies.

Tetra Bio-Pharma held a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) in late January to advance its PPP001 clinical trial. During the meeting, the FDA provided all the necessary guidance on the design of a Phase I clinical trial on healthy volunteers and its overall development program. The meeting further demonstrates the agency’s willingness to continue the clinical trial to develop a dried marijuana prescription drug.

PPP001 is a dried cannabis product with 9.5% tetrahydrocannabinol (“THC”) and 2% cannabidiol (“CBD”) that is being developed as a prescription drug that will meet the FDA’s high bar for quality and manufacturing. The company’s goal is to be the first to achieve reimbursement from insurance companies for the cost of the prescription, which could prove to be a game-changer for would-be medical marijuana patients that cannot afford the drug.

Tetra Bio-Pharma recently partnered with Sante Cannabis in Montreal to assist in developing its clinical trials. As a leading private medical marijuana clinic, the organization has years of experience in educating patients and ensuring the optimal benefits. The company aims to leverage this expertise to ensure that its clinical trials are properly designed to achieve desired outcomes while helping achieve the organization’s goal of lowering costs for patients.

Please follow the link to read the full article and see the interview: http://www.cannabisfn.com/tetra-bio-pharma-moves-closer-to-clinical-trials/

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

 

VIDEO FEATURE: New Age Metals – 121 Mining Investment Cape Town 2017 $NAM.ca

Posted by AGORACOM-JC at 4:32 PM on Monday, February 13th, 2017

Namaste Applies to Trade on OTCQB $N.ca

Posted by AGORACOM-JC at 10:48 AM on Monday, February 13th, 2017

Nlogo

  • Applied for approval from OTC Markets Group to trade the Company’s common shares on the OTCQB Venture Market
  • Company will provide further updates to investors relating to the trading of its common shares on OTCQB in due course

VANCOUVER, BRITISH COLUMBIA–(Feb. 13, 2017) - Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) is pleased to announce that it has applied for approval from OTC Markets Group to trade the Company’s common shares on the OTCQB Venture Market. Approval from OTC Markets Group is subject to the approval of Form 211 by FINRA, which has been filed by Canaccord Genuity Inc. as a market maker in the common shares, and is currently pending approval. The Company will provide further updates to investors relating to the trading of its common shares on OTCQB in due course.

Sean Dollinger, President and CEO of Namaste, comments: “Namaste has developed a significant US presence over the last year and believes trading our shares on the OTCBQ is a natural way to broaden awareness of our company with US investors. We look forward to completing this process and generating awareness of our company in the US markets.”

About OTC Markets Group Inc.

OTC Markets Group Inc. operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 US and global securities. Through OTC Link® ATS, the company connects a diverse network of broker-dealers that provide liquidity and execution services. The company enables investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 e-commerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Further information on the company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to several factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+ 1 (786) 389-9771
info@namastevapes.com
www.namastetechnologies.com

Pacific North West Capital Announces Effective Date of Share Consolidation and Name Change $PFN.ca

Posted by AGORACOM-JC at 4:35 PM on Tuesday, January 31st, 2017

Hublogo1 copy

  • Received approval to implement its proposed three (3) old for one (1) new share consolidation and name change to New Age Metals Inc.
  • Effective at the opening of the market on February 1, 2017 the common shares of Pacific North West Capital Corp. will be delisted and the post-consolidated shares of New Age Metals Inc. will begin trading on the TSX Venture Exchange under its new trading symbol “NAM”

Vancouver, British Columbia / January 31, 2017 - Pacific North West Capital Corp. (“PFN”) (TSXV: PFN OTCQB: PAWEF FSE: P7J) announces that further to news release of January 25, 2017, PFN has received approval to implement its proposed three (3) old for one (1) new share consolidation and name change to New Age Metals Inc. (the “Company”). Effective at the opening of the market on February 1, 2017 the common shares of Pacific North West Capital Corp. will be delisted and the post-consolidated shares of New AgeMetals Inc. will begin trading on the TSX Venture Exchange under its new trading symbol “NAM”.

Letters of transmittal will be sent to the registered shareholders providing instructions to surrender the share certificates evidencing their pre-consolidated common shares for replacement certificates of New Age Metals Inc. representing the number of post-consolidated common shares they are entitled to as a result of the consolidation. Until surrendered, each certificate representing the pre-consolidated common shares will be deemed to represent the number of post-consolidated common shares of New Age Metals Inc. that the holder thereof is entitled to as a result of the consolidation. The Company will not be issuing fractional shares as a result of the consolidation. Instead, all fractional shares equal or greater to one-half will be rounded to the next whole share.

The Company’s website, newagemetals.com, is currently under construction and is slated for completion in the upcoming days. During this transition period, please visit pfncapital.com for more information about the Company’s projects.

On behalf of the Board of Directors

“Harry Barr”

Harry G. Barr

Chairman and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”, “anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”, “prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company’s ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forward-looking statements.

INTERVIEW: American Creek Discusses the Invaluable addition of Jeff Kyba P.Geo to the Team $AMK.ca

Posted by AGORACOM-JC at 8:10 AM on Tuesday, January 31st, 2017

  • American Creek Resources is a precious metals exploration company with an impressive portfolio of high-potential gold and silver projects in British Columbia.  These include properties in B.C.’s prolific Golden Triangle, one of the richest areas of mineralization in the world.
  • MTJLS Mineralization in the Treaty Creek claims area lies within the same broad hydrothermal system that generated the several deposits on the Seabridge Gold KSM and the Pretivm Brucejack properties that lie immediately southwest of the Treaty Creek claims
  • So far over 130 million ounces of gold, 800 million ounces of silver and 20 billion pounds of copper (all categories included), representing one of the greatest concentrations of metal value on the planet, have been delineated within the geological system shared by KSM, Brucejack, and Treaty Creek.

Hub On AGORACOM / Corporate Profile / Watch Interview!